scholarly article | Q13442814 |
P356 | DOI | 10.1200/JCO.2012.47.3009 |
P698 | PubMed publication ID | 23980090 |
P50 | author | Josep M. Llovet | Q37393125 |
Jordi Bruix | Q37393143 | ||
Valérie Boige | Q41786186 | ||
Won Young Tak | Q43284953 | ||
Philippe Mathurin | Q54835963 | ||
Thomas Decaens | Q62096202 | ||
Jean-Luc Raoul | Q88195042 | ||
Joong-Won Park | Q90067942 | ||
Eveline Boucher | Q90445694 | ||
P2093 | author name string | Ian Walters | |
Richard S Finn | |||
Masatoshi Kudo | |||
Laetitia Fartoux | |||
Yoon-Koo Kang | |||
Deng-Yn Lin | |||
Ho-Yeong Lim | |||
Ronnie T Poon | |||
Morris Sherman | |||
David Liu | |||
Eric Assenat | |||
Yee Chao | |||
Charissa Chang | |||
Jean-Frédéric Blanc | |||
Rana Ezzeddine | |||
P433 | issue | 28 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatocellular carcinoma | Q1148337 |
patient | Q181600 | ||
P304 | page(s) | 3509-3516 | |
P577 | publication date | 2013-08-26 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study | |
P478 | volume | 31 |
Q64272871 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
Q91599660 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
Q89558091 | 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations |
Q53212995 | A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib. |
Q33442349 | A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. |
Q48036796 | A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma |
Q92855692 | A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma |
Q53826807 | A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. |
Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
Q85364824 | A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma |
Q87691280 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma |
Q36697575 | A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer |
Q38669565 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study |
Q36223538 | A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib |
Q53839706 | A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. |
Q33419633 | A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. |
Q38848537 | Advanced Hepatocellular Cancer: the Current State of Future Research |
Q26851033 | Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up |
Q38697243 | Advances in Local and Systemic Therapies for Hepatocellular Cancer |
Q38210345 | Advances in managing hepatocellular carcinoma |
Q38521011 | Advances in targeted therapies for hepatocellular carcinoma in the genomic era. |
Q58700934 | Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials |
Q47954829 | An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma |
Q28075305 | Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma |
Q39210287 | Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? |
Q33770680 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions |
Q55544709 | Anti-proliferative Effect of 15,16-Dihydrotanshinone I Through Cell Cycle Arrest and the Regulation of AMP-activated Protein Kinase/Akt/mTOR and Mitogen-activated Protein Kinase Signaling Pathway in Human Hepatocellular Carcinoma Cells. |
Q42371684 | Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review |
Q96348711 | Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma |
Q41962614 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update |
Q49545623 | Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib |
Q57762740 | Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial |
Q55129610 | CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. |
Q89057713 | Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma |
Q64092687 | Cabozantinib for advanced hepatocellular carcinoma |
Q56373211 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma |
Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
Q28076867 | Challenges of advanced hepatocellular carcinoma |
Q50169188 | Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. |
Q35501246 | Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges |
Q41706847 | Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives |
Q37708002 | Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. |
Q38639762 | Chemotherapy for hepatocellular carcinoma: The present and the future |
Q47775953 | Chemotherapy for hepatocellular carcinoma: current status and future perspectives |
Q92482087 | CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma |
Q33594931 | Cirrhosis and its complications: evidence based treatment |
Q42093061 | Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma |
Q37289933 | Clinical implications of basic research in hepatocellular carcinoma |
Q38350799 | Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review |
Q38743040 | Clinical trials of antiangiogenic therapy for hepatocellular carcinoma |
Q28077738 | Combination treatment including targeted therapy for advanced hepatocellular carcinoma |
Q92126376 | Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States |
Q30245396 | Comparison of hepatocellular carcinoma in Eastern versus Western populations. |
Q40218092 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options |
Q89623916 | Controversies in the management of hepatocellular carcinoma |
Q38702281 | Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. |
Q38155511 | Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition |
Q64959827 | Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. |
Q38410816 | Current management of hepatocellular carcinoma: an Eastern perspective |
Q38843057 | Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma |
Q27026036 | Current systemic treatment of hepatocellular carcinoma: A review of the literature |
Q34992813 | DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors |
Q58011404 | Das hepatozelluläre Karzinom |
Q38962057 | Decoding hepatocellular carcinoma: the promise of microRNAs |
Q26752854 | Development and novel therapeutics in hepatocellular carcinoma: a review |
Q38201707 | Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. |
Q55003380 | Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. |
Q38184582 | Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy |
Q39062384 | Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity |
Q34467228 | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. |
Q92895892 | Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial |
Q34458068 | Drug development for hepatocellular carcinoma: knowing the past helps to understand the future |
Q27004410 | Drug therapy for advanced-stage liver cancer |
Q34458029 | Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study |
Q58802297 | Emerging therapies in advanced hepatocellular carcinoma |
Q39366121 | Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma |
Q35739362 | Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma |
Q90136508 | Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis |
Q94541665 | Evolution of Systemic Therapy for Hepatocellular Carcinoma |
Q55440708 | FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. |
Q57073605 | Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials |
Q41595439 | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies |
Q38923517 | Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma |
Q28073654 | First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation |
Q37631655 | From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers |
Q33414726 | Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies |
Q47576283 | Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. |
Q38184833 | HCC therapies--lessons learned |
Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
Q90095535 | Hepatocellular Carcinoma-How to Determine Therapeutic Options |
Q42053469 | Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy |
Q54977952 | Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. |
Q28079378 | Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment |
Q57756376 | Hepatocellular carcinoma |
Q58020832 | Hepatocellular carcinoma |
Q38207012 | Hepatocellular carcinoma review: current treatment, and evidence-based medicine |
Q38554626 | Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? |
Q39307416 | Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists |
Q91784372 | Hepatocellular carcinoma treatment: hurdles, advances and prospects |
Q26828407 | Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting |
Q92104133 | Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets |
Q28084046 | Hepatocellular carcinoma: Where there is unmet need |
Q26741201 | Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? |
Q35112053 | Hepatocellular carcinoma: clinical frontiers and perspectives |
Q33895113 | Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies |
Q38246965 | Hepatocellular carcinoma: systemic therapies and future perspectives |
Q90644106 | Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials |
Q91942647 | Implications of Immunotherapy in Hepatobiliary Tumors |
Q92353495 | Insights into the success and failure of systemic therapy for hepatocellular carcinoma |
Q48226736 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. |
Q61805290 | Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date |
Q34786090 | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial |
Q38176242 | Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. |
Q35903794 | Liver cancer: Approaching a personalized care |
Q38686790 | Locoregional and systemic therapy for hepatocellular carcinoma |
Q58704728 | Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? |
Q92666152 | Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma |
Q38444096 | MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. |
Q27014423 | MET inhibitors for treatment of advanced hepatocellular carcinoma: A review |
Q89057715 | Management of Hepatocellular Carcinoma in Japan as a World-Leading Model |
Q87664325 | Management of hepatocellular carcinoma |
Q48105164 | Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation |
Q35550210 | MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A |
Q34974386 | Minimally invasive local therapies for liver cancer |
Q36968841 | Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators |
Q89861316 | Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma |
Q42317924 | Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives |
Q42169289 | Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now? |
Q37631288 | Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition |
Q47121307 | Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review |
Q38151670 | Molecular targeted therapy for hepatocellular carcinoma: current and future |
Q38212573 | Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future |
Q57143856 | Molecular therapies and precision medicine for hepatocellular carcinoma |
Q26766689 | Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? |
Q38233004 | Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. |
Q35434188 | Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. |
Q89528234 | New landscapes and horizons in hepatocellular carcinoma therapy |
Q38282800 | New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions |
Q96134073 | Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline |
Q38537138 | Novel drugs in clinical development for hepatocellular carcinoma |
Q37542835 | Novel implications in the treatment of hepatocellular carcinoma |
Q47108754 | Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. |
Q57821063 | Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma |
Q38248240 | Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review |
Q26738860 | Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection |
Q38864682 | PharmGKB summary: sorafenib pathways |
Q92446420 | Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors |
Q64949220 | Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. |
Q33433311 | Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. |
Q39109076 | Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). |
Q36204431 | Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients |
Q49168467 | Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma |
Q40106296 | Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib |
Q38660065 | Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial |
Q41761530 | Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit? |
Q41489415 | Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. |
Q98241469 | Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis |
Q38864396 | Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment |
Q26740217 | Progress in systemic therapy of advanced hepatocellular carcinoma |
Q51743178 | Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. |
Q41344288 | Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. |
Q30236010 | Recent advances in hepatocellular carcinoma therapy |
Q26863748 | Recent advances in multidisciplinary management of hepatocellular carcinoma |
Q57216547 | Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study |
Q42380812 | Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma |
Q38648119 | Regorafenib as treatment for patients with advanced hepatocellular cancer |
Q38785510 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial |
Q38674803 | Regorafenib for the treatment of unresectable hepatocellular carcinoma. |
Q50069191 | Regorafenib for treatment of hepatocellular carcinoma. |
Q47950809 | Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment |
Q55600804 | Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. |
Q33944599 | Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer |
Q90436245 | Review article: systemic treatment of hepatocellular carcinoma |
Q28551983 | Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials |
Q47869247 | Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma |
Q34728237 | Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. |
Q34259112 | Role of liver stem cells in hepatocarcinogenesis |
Q28070762 | Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma |
Q38354294 | Role of the fibroblast growth factor receptor axis in cholangiocarcinoma |
Q38789875 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial |
Q55266511 | Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. |
Q38971537 | Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure |
Q38264330 | Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. |
Q37688967 | Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis |
Q64058271 | Second-line treatment options in hepatocellular carcinoma |
Q94543854 | Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors |
Q30240170 | Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC. |
Q64911371 | Sorafenib for the treatment of hepatocellular carcinoma. |
Q98460342 | Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial |
Q87226010 | Sorafenib use in hepatocellular carcinoma: more questions than answers |
Q38544841 | Sorafenib: 10 years after the first pivotal trial. |
Q60922494 | Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma |
Q90288455 | Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
Q38708569 | Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. |
Q42343451 | Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future |
Q58093758 | Systemic Therapy for Hepatocellular Carcinoma: Latest Advances |
Q49907735 | Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies |
Q33593213 | Systemic therapy for advanced hepatocellular carcinoma: an update |
Q26865844 | Systemic therapy of hepatocellular carcinoma: current status and future perspectives |
Q38824017 | Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. |
Q39112745 | Systemic treatment for hepatocellular carcinoma: Still unmet expectations |
Q97542924 | Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies |
Q38933836 | Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? |
Q57301434 | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
Q39295492 | TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials |
Q57055294 | Targeted and Immune-based Therapies for Hepatocellular Carcinoma |
Q64122405 | Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond |
Q37702506 | Targeted therapy in gastrointestinal malignancies |
Q42343453 | Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. |
Q98946916 | Targeting angiogenesis for liver cancer: Past, present, and future |
Q38923977 | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
Q47965755 | Targets for immunotherapy of liver cancer. |
Q46027563 | The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015): Evidence and Consensus on HCC Management. |
Q64962531 | The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study. |
Q58797003 | The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma |
Q50579308 | The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. |
Q38754534 | The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma |
Q57053754 | The Role of Angiogenesis in Hepatocellular Carcinoma |
Q48707409 | The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. |
Q38635474 | The biology of Hepatocellular carcinoma: implications for genomic and immune therapies |
Q44479261 | The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib |
Q34402325 | The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 |
Q52645823 | The role of tumor microenvironment in resistance to anti-angiogenic therapy. |
Q92618573 | The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells |
Q38497265 | Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. |
Q56384328 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study |
Q38259343 | Tivantinib: critical review with a focus on hepatocellular carcinoma. |
Q47132493 | Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma |
Q38217737 | Treating advanced hepatocellular carcinoma: How to get out of first gear |
Q40955279 | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
Q38236876 | Treatment of intermediate-stage hepatocellular carcinoma |
Q47832831 | Treatment options after sorafenib failure in patients with hepatocellular carcinoma. |
Q64116366 | Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report |
Q95282127 | Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference |
Q37687269 | Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib |
Q39393740 | Tumor angiogenesis revisited: Regulators and clinical implications. |
Q42292467 | Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. |
Q52654643 | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. |
Q26797535 | Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma |
Q92628462 | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE) |
Q47818290 | Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. |
Q42560671 | Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? |
Q86758819 | [Therapy of hepatocellular carcinoma] |
Q39032512 | mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib |
Q36771900 | pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma |
Search more.